# Aripiprazole in Adolescents With Schizophrenia

> **NCT00102063** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 302 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole tablet, 10 mg
- **DRUG:** Aripiprazole tablet, 30 mg
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT00102063
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2012-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102063, "Aripiprazole in Adolescents With Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00102063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*